BRAF and non-small cell lung carcinoma: Apart from the MAPK pathway, we also observed that STK11 and KEAP1, which are also often co-mutated in KRAS-mutant NSCLC, are more frequently co-mutated with class II or III BRAF mutations compared to class I variants21.